Skip to main content

Apitegromab Dosing Calculator

Pre-filled with the most-reported community reconstitution protocol for Apitegromab. See how 1 mL and 2 mL of bacteriostatic water change concentration and syringe-draw volume, then adjust the calculator below for your own vial.

Quick answer · Community-reported standard

A 60 mg vial of Apitegromab reconstituted with 2 mL of bacteriostatic water yields a concentration of 30.00 mg/mL. At that concentration, a 20 mg dose of Apitegromab equals 66.7 units on a U-100 insulin syringe (0.667 mL). Apitegromab is typically administered once daily via intravenous infusion.

Apitegromab reconstitution: 1 mL vs 2 mL bac water

Bacteriostatic water volume is flexible. Less water means higher concentration and smaller injection volumes; more water means lower concentration and easier dose precision. Both options below are valid for a 60 mg vial.

BAC water addedConcentrationVolume per 20 mg doseDraw on U-100 syringe (units)
1 mL60.00 mg/mL0.333 mL33.3 units
2 mL30.00 mg/mL0.667 mL66.7 units
Based on a 60 mg vial of Apitegromab reconstituted with bacteriostatic water. Insulin-syringe units assume a standard U-100 syringe (100 units = 1 mL).

Calculate your Apitegromab dose

Alternative Apitegromab protocols

Beyond the default above, Apitegromab is also reported in the following protocols. Use these as starting points and recalculate with the tool above.

EMBRAZE Obesity Protocol

Community
Dose
Dose not yet publicly disclosed in detail
Frequency
Every 4 weeks
Duration
Phase 2 trial ongoing
Route
Intravenous infusion

Investigational combination with tirzepatide for lean mass preservation during weight loss

SMA Motor Function (SAPPHIRE Phase 3)

Clinical
Dose
Apitegromab 10 mg/kg or 20 mg/kg IV every 4 weeks for 12 months in nonambulatory patients with Types 2 and 3 SMA aged 2-21 receiving nusinersen or risdiplam. Both doses contributed to a pooled 1.8-point HFMSE improvement over placebo (p=0.019).
Frequency
IV infusion every 4 weeks (Q4W)
Duration
12 months in the pivotal study

Randomized 1:1:1 to 10 mg/kg, 20 mg/kg, or placebo. Primary analysis pooled both dose groups. Individual dose-response differentiation not clearly reported. Background SMN-targeted therapy required in all participants.

SMA Motor Function (TOPAZ Phase 2)

Clinical
Dose
Apitegromab 2, 10, or 20 mg/kg IV every 4 weeks in patients with Types 2 and 3 SMA aged 2-21. The 20 mg/kg dose in nonambulatory patients receiving nusinersen showed the strongest HFMSE improvements at 36-48 months.
Frequency
IV infusion every 4 weeks (Q4W)
Duration
12 months core study, extended to 48 months

Open-label active treatment design (no placebo). Long-term extension data showed sustained motor function gains. 48-month HFMSE change of +5.3 points at 20 mg/kg with nusinersen.

Obesity/Lean Mass Preservation (EMBRAZE Phase 2)

Clinical
Dose
Apitegromab 10 mg/kg IV every 4 weeks in combination with tirzepatide in adults with BMI >=27 with comorbidities or BMI >=30. Preserved 54.9% of lean mass (p=0.001) vs tirzepatide alone at 24 weeks.
Frequency
IV infusion every 4 weeks (Q4W)
Duration
24 weeks

Proof-of-concept trial (n=100). Randomized 1:1 to apitegromab or placebo, all receiving tirzepatide. No serious adverse events or discontinuations related to apitegromab. Scholar Rock plans to develop SRK-439 (next-generation inhibitor) for the obesity indication.

Phase 1 Dose-Finding (Healthy Adults)

Clinical
Dose
Single ascending doses of 1, 3, 10, 20, 30 mg/kg IV and multiple ascending doses of 10, 20, 30 mg/kg IV in healthy adults. Linear, dose-proportional pharmacokinetics with half-life of 24-31 days.
Frequency
Single dose or multiple doses IV
Duration
Variable (Phase 1)

Safe and well-tolerated at all doses up to 30 mg/kg. No anti-drug antibodies detected. Dose-dependent target engagement confirmed by serum latent myostatin increases.

Apitegromab reconstitution & storage

Apitegromab is supplied as a sterile solution for IV infusion in clinical trial settings. It does not require reconstitution by end users. All preparation and administration occurs within clinical trial sites under medical supervision.

As a monoclonal antibody, apitegromab requires refrigerated storage (2-8 degrees C) and protection from light. It must not be frozen. Storage and handling are managed by clinical trial sites per sponsor protocols.

Apitegromab dosing FAQ

How much bacteriostatic water should I add to a 60 mg vial of Apitegromab?

The community standard is 2 mL of bacteriostatic water for a 60 mg Apitegromab vial. That gives a concentration of 30.00 mg/mL, so a 20 mg dose is 66.7 units on a U-100 insulin syringe. Adding 1 mL instead doubles the concentration to 60.00 mg/mL and halves the draw to 33.3 units. Less water = smaller injection volume but harder to measure precisely.

How many syringe units is a 20 mg dose of Apitegromab?

On a standard U-100 insulin syringe, a 20 mg dose of Apitegromab is 66.7 units when the 60 mg vial is reconstituted with 2 mL of bacteriostatic water (30.00 mg/mL). If you use 1 mL of bac water instead, draw 33.3 units (60.00 mg/mL).

What is the standard Apitegromab dose?

Community-reported protocols for Apitegromab typically use 20 mg once daily via Intravenous infusion. 20 mg is a common starting dose. Phase 3 clinical trial protocol; not yet commercially available

How long does a vial of Apitegromab last at 20 mg once daily?

A 60 mg vial of Apitegromab contains roughly 3 doses at 20 mg per injection. At once daily dosing, that is approximately 3 days (about 0 weeks) of supply per vial. Reconstituted Apitegromab should generally be used within 28 days when refrigerated.

Where do you inject Apitegromab?

Apitegromab is typically administered intravenous infusion. Common subcutaneous sites are the lower abdomen (at least an inch from the navel), the outer thigh, and the love handles. Rotate sites with each injection to reduce localized irritation and bruising.

Can I use sterile water instead of bacteriostatic water for Apitegromab?

Bacteriostatic water (containing 0.9% benzyl alcohol as a preservative) is strongly preferred for multi-dose vials like Apitegromab because it inhibits microbial growth and lets a single vial be used over multiple weeks. Sterile water has no preservative and should generally be reserved for single-use preparations only.

More on Apitegromab

⚠️

Medical Disclaimer

This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.